Related Experiment Video
Updated: May 31, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Platelet count for predicting fibrosis in nonalcoholic fatty liver disease
Masato Yoneda1, Hideki Fujii, Yoshio Sumida
1Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Insights
Platelet count is a cost-effective biomarker for assessing liver fibrosis severity in nonalcoholic fatty liver disease (NAFLD) patients. This simple blood test aids in predicting fibrosis stages, improving patient management and recruitment for clinical trials.
Area of Science:
- Hepatology
- Clinical Diagnostics
- Biomarker Research
Background:
- Liver fibrosis severity is crucial for nonalcoholic fatty liver disease (NAFLD) prognosis and treatment.
- Liver biopsy, the gold standard for fibrosis assessment, is impractical for all NAFLD patients.
- Non-invasive methods are needed to accurately assess liver fibrosis in NAFLD.
Purpose of the Study:
- To evaluate the clinical utility of platelet count for predicting liver fibrosis severity in Japanese NAFLD patients.
- To determine the accuracy of platelet count in identifying significant fibrosis stages.
- To establish platelet count as a reliable non-invasive biomarker for NAFLD fibrosis.
Main Methods:
- Retrospective analysis of 1,048 Japanese NAFLD patients with biopsy-confirmed fibrosis.
- Laboratory evaluations, including platelet count, were performed for all participants.
- Statistical analysis using receiver operating characteristic (ROC) curves to assess diagnostic performance.
Main Results:
- A significant inverse correlation was observed between platelet count and liver fibrosis stage.
- Platelet count demonstrated good diagnostic performance for Stage 3 fibrosis (AUC=0.774) and excellent performance for Stage 4 fibrosis (AUC=0.918).
- Optimal cutoff values were identified for predicting advanced fibrosis stages.
Conclusions:
- Platelet count is a simple, cost-effective, and accurate biomarker for assessing liver fibrosis severity in NAFLD.
- Utilizing validated platelet count cutoffs can facilitate efficient patient recruitment for clinical studies.
- Platelet count offers a practical alternative to liver biopsy for fibrosis staging in NAFLD.
Background:
The severity of liver fibrosis is known to be a good indicator for surveillance, and for determining the prognosis and optimal treatment of nonalcoholic fatty liver disease (NAFLD). However, it is virtually impossible to carry out liver biopsies in all NAFLD patients. The purpose of this study was to investigate the clinical usefulness of measuring the platelet count for predicting the severity of liver fibrosis in a large retrospective cohort of Japanese patients with NAFLD.
Methods:
A total of 1,048 patients with liver-biopsy-confirmed NAFLD seen between 2002 and 2008 were enrolled from nine hepatology centers in Japan. Laboratory evaluations were performed for all patients.
Results:
A linear decrease of the platelet count with increasing histological severity of hepatic fibrosis was revealed. The area under the receiver operating characteristic curve estimating the diagnostic performance of the platelet count for hepatic fibrosis Stage 3 was 0.774 (optimal cutoff value, 19.2 × 10(4)/μl; sensitivity, 62.7%; specificity, 76.3%), and that for Stage 4 was 0.918 (optimal cutoff value, 15.3 × 10(4)/μl; sensitivity, 80.5%; specificity, 88.8%).
Conclusions:
The platelet count may be an ideal biomarker of the severity of fibrosis in NAFLD patients, because it is simple, easy to measure and handle, cost-effective, and accurate for predicting the severity of fibrosis. Furthermore, by using the platelet count cutoff value validated in our multiple large trials, efficient recruitment of NAFLD patients may be facilitated.
Related Concept Videos
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:23Cirrhosis I: Introduction
01:24Cirrhosis II: Pathophysiology